Regulus Therapeutics Inc. – NASDAQ:RGLS

Regulus Therapeutics stock price today

$8.05
+6.51
+422.73%
Financial Health
0
1
2
3
4
5
6
7
8
9

Regulus Therapeutics stock price monthly change

-9.94%
month

Regulus Therapeutics stock price quarterly change

-9.94%
quarter

Regulus Therapeutics stock price yearly change

+17.56%
year

Regulus Therapeutics key metrics

Market Cap
100.20M
Enterprise value
N/A
P/E
-0.53
EV/Sales
N/A
EV/EBITDA
0.07
Price/Sales
N/A
Price/Book
0.44
PEG ratio
-0.01
EPS
-1.46
Revenue
N/A
EBITDA
-31.97M
Income
-31.36M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Regulus Therapeutics stock price history

Regulus Therapeutics stock forecast

Regulus Therapeutics financial statements

Regulus Therapeutics Inc. (NASDAQ:RGLS): Profit margin
Jun 2023 0 -7.01M
Sep 2023 0 -7.82M
Dec 2023 302K -8.06M -2669.21%
Mar 2024 0 -8.46M
Regulus Therapeutics Inc. (NASDAQ:RGLS): Analyst Estimates
Sep 2025 0 -3.23M
Oct 2025 0 -5.60M
Dec 2025 0 -3.95M
Dec 2025 0 -5.60M
  • Analysts Price target

  • Financials & Ratios estimates

Regulus Therapeutics Inc. (NASDAQ:RGLS): Debt to assets
Jun 2023 43647000 9.65M 22.11%
Sep 2023 37747000 9.48M 25.14%
Dec 2023 30750000 9.56M 31.1%
Mar 2024 114138000 6.55M 5.74%
Regulus Therapeutics Inc. (NASDAQ:RGLS): Cash Flow
Jun 2023 -6.25M 0 13.20M
Sep 2023 -6.27M -5.44M 287K
Dec 2023 -6.12M 4.93M -873K
Mar 2024 -8.74M -78.54M 93.10M

Regulus Therapeutics alternative data

Regulus Therapeutics Inc. (NASDAQ:RGLS): Employee count
Aug 2023 31
Sep 2023 30
Oct 2023 30
Nov 2023 30
Dec 2023 29
Jan 2024 29
Feb 2024 29
Mar 2024 30
Apr 2024 30
May 2024 30
Jun 2024 30
Jul 2024 28

Regulus Therapeutics other data

35.50% -18.72%
of RGLS is owned by hedge funds
5.41M -2.69M
shares is hold by hedge funds

Regulus Therapeutics Inc. (NASDAQ:RGLS): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 25516
Transaction Date Insider Security Shares Price per share Total value Source
Sale
CALSADA CRISPINA officer: Chief Financial Officer
Common Stock 5,468 $1.19 $6,512
Sale
AKER CHRISTOPHER RAY officer: Sr. VP &.. Common Stock 5,468 $1.19 $6,512
Sale
HAGAN JOSEPH P director, officer: Chief Execut..
Common Stock 14,580 $1.19 $17,365
Purchase
DRYGIN DENIS officer: Chief Scientific Officer
Common Stock 76,686 $0.23 $17,638
Purchase
DRYGIN DENIS officer: Chief Scientific Officer
Common Stock 23,314 $0.23 $5,362
Purchase
HAGAN JOSEPH P director, officer: President an..
Common Stock 100,000 $0.22 $21,500
Sale
AKER CHRISTOPHER RAY officer: Sr. VP &.. Common Stock 860 $0.89 $765
Sale
HAGAN JOSEPH P director, officer: President an..
Common Stock 4,186 $0.89 $3,726
Sale
HAGAN JOSEPH P director, officer: President an..
Common Stock 8,288 $0.86 $7,128
Sale
AKER CHRISTOPHER RAY officer: Sr. VP &.. Common Stock 828 $1.72 $1,424
Patent
Application
Filling date: 21 Mar 2022 Issue date: 7 Jul 2022
Application
Filling date: 12 Nov 2019 Issue date: 31 Mar 2022
Application
Filling date: 19 Jul 2019 Issue date: 31 Mar 2022
Application
Filling date: 5 Oct 2021 Issue date: 27 Jan 2022
Application
Filling date: 7 May 2019 Issue date: 10 Jun 2021
Application
Filling date: 16 Oct 2020 Issue date: 15 Apr 2021
Application
Filling date: 25 Sep 2020 Issue date: 1 Apr 2021
Grant
Filling date: 17 Jan 2019 Issue date: 9 Mar 2021
Application
Filling date: 27 Aug 2020 Issue date: 17 Dec 2020
Application
Filling date: 27 Aug 2020 Issue date: 17 Dec 2020
Insider Compensation
Mr. Joseph P. Hagan M.B.A. (1969) Pres, Chief Executive Officer & Director
$826,080
Mr. Christopher Ray Aker J.D. (1961) Senior Vice President, Gen. Counsel & Corporation Sec. $457,470
Tuesday, 26 November 2024
prnewswire.com
Thursday, 7 November 2024
prnewswire.com
Tuesday, 8 October 2024
prnewswire.com
Wednesday, 28 August 2024
prnewswire.com
Thursday, 8 August 2024
prnewswire.com
Tuesday, 6 August 2024
prnewswire.com
Tuesday, 9 July 2024
prnewswire.com
Monday, 24 June 2024
prnewswire.com
Tuesday, 4 June 2024
prnewswire.com
Thursday, 16 May 2024
prnewswire.com
Thursday, 9 May 2024
prnewswire.com
Tuesday, 7 May 2024
investorplace.com
Monday, 6 May 2024
prnewswire.com
Tuesday, 30 April 2024
prnewswire.com
Wednesday, 10 April 2024
seekingalpha.com
Thursday, 21 March 2024
prnewswire.com
Wednesday, 13 March 2024
Zacks Investment Research
Wednesday, 22 November 2023
PRNewsWire
Wednesday, 23 August 2023
GuruFocus
Friday, 14 April 2023
Zacks Investment Research
Thursday, 10 November 2022
Seeking Alpha
Tuesday, 13 September 2022
Zacks Investment Research
PennyStocks
Friday, 2 September 2022
PRNewsWire
Thursday, 11 August 2022
Seeking Alpha
Friday, 27 May 2022
PennyStocks
Monday, 23 May 2022
PennyStocks
Tuesday, 17 May 2022
PRNewsWire
InvestorPlace
Sunday, 15 May 2022
PennyStocks
  • What's the price of Regulus Therapeutics stock today?

    One share of Regulus Therapeutics stock can currently be purchased for approximately $8.05.

  • When is Regulus Therapeutics's next earnings date?

    Unfortunately, Regulus Therapeutics's (RGLS) next earnings date is currently unknown.

  • Does Regulus Therapeutics pay dividends?

    No, Regulus Therapeutics does not pay dividends.

  • How much money does Regulus Therapeutics make?

    Regulus Therapeutics has a market capitalization of 100.20M.

  • What is Regulus Therapeutics's stock symbol?

    Regulus Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "RGLS".

  • What is Regulus Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Regulus Therapeutics?

    Shares of Regulus Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Regulus Therapeutics's key executives?

    Regulus Therapeutics's management team includes the following people:

    • Mr. Joseph P. Hagan M.B.A. Pres, Chief Executive Officer & Director(age: 56, pay: $826,080)
    • Mr. Christopher Ray Aker J.D. Senior Vice President, Gen. Counsel & Corporation Sec.(age: 64, pay: $457,470)
  • How many employees does Regulus Therapeutics have?

    As Jul 2024, Regulus Therapeutics employs 28 workers, which is 7% less then previous month and 7% less then previous quarter.

  • When Regulus Therapeutics went public?

    Regulus Therapeutics Inc. is publicly traded company for more then 12 years since IPO on 9 Oct 2012.

  • What is Regulus Therapeutics's official website?

    The official website for Regulus Therapeutics is regulusrx.com.

  • Where are Regulus Therapeutics's headquarters?

    Regulus Therapeutics is headquartered at 4224 Campus Point Court, San Diego, CA.

  • How can i contact Regulus Therapeutics?

    Regulus Therapeutics's mailing address is 4224 Campus Point Court, San Diego, CA and company can be reached via phone at 858 202 6300.

Regulus Therapeutics company profile:

Regulus Therapeutics Inc.

regulusrx.com
Exchange:

NASDAQ

Full time employees:

32

Industry:

Biotechnology

Sector:

Healthcare

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

4224 Campus Point Court
San Diego, CA 92121

CIK: 0001505512
ISIN: US75915K3095
CUSIP: 75915K309